Journal of Clinical Oncology
Articles in this Issue
NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal
PURPOSE In the previously completed NCI9673 (part A) single-arm study, the antiprogrammed death (PD)–ligand-1 antibody nivolumab demonstrated efficacy for patients with metastatic...
BRUIN 313 and 314 Trials Open the Door for Noncovalent Bruton Tyrosine Kinase Inhibition as Initial Therapy for Chronic Lymphocytic Leukemia
Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826
We present a subset analysis on the adolescent cohort of the S1826 randomized phase three trial, comparing nivolumab, doxorubicin, vinblastine, dacarbazine (N-AVD) to brentuximab vedotin-AVD (BV-AVD)...
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
PURPOSE Pirtobrutinib, a highly selective, noncovalent Bruton tyrosine kinase inhibitor (BTKi), has shown efficacy and safety in patients with chronic lymphocytic leukemia/small ly...
North Star
North Star is a luminous, gut-honest reflection by a pediatric oncologist that reminds us that beyond protocols and outcomes, the deepest medicine is presence.
Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor–Positive Breast Cancer: A Cohort Study
PURPOSE To evaluate the clinical benefit of extended endocrine therapy (eET) after 5 years of adjuvant treatment with luteinizing hormone-releasing hormone agonists (LHRHa) in prem...
Methodologic and Reporting Gaps in the SURF Trial
Reply to: “Revisiting Methodologic Paradigms in Local Therapies for Hepatocellular Carcinoma: Insights From the SURF Study” and “Methodologic and Reporting Gaps in the SURF Trial”
Bridging the Gap: Pirtobrutinib for Treatment-Naïve Chronic Lymphatic Leukemia
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1
This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the...
Hepatic Arterial Infusion Pump Chemotherapy in Patients With Unresectable Intrahepatic Cholangiocarcinoma—PUMP-2 Trial
PURPOSE The 3-year overall survival (OS) for advanced intrahepatic cholangiocarcinoma (iCCA) confined to the liver after systemic chemotherapy with gemcitabine-cisplatin (gem-cis)...
Therapeutic Considerations in Early-Stage, Estrogen Receptor–Positive, <i>BRCA</i> -Associated Breast Cancer
BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
PURPOSE BRUIN CLL-313 is a randomized, open-label, global phase III study comparing the efficacy and safety of pirtobrutinib, a highly selective, noncovalent Bruton tyrosine kinase...